Who
Elissa S. Cote
Chief Corp Development Officer
Company insider
Files Form 4 as: Chief Corp Development Officer, Vistagen Therapeutics.
In numbers
- Trades disclosed
- 3
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 23 Jun 2025
- Last trade
- 7 Apr 2026
- Last filed
- 9 Apr 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Apr 2026filed 9 Apr 2026 | VTGN Vistagen Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 7 Apr 2026filed 9 Apr 2026 | VTGN Vistagen Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 23 Jun 2025filed 25 Jun 2025 | VTGN Vistagen Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.